IP Library Patent Application 14387704
Patent Application
App. No. 14/387,704

HUMANIZED MOUSE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/387,704
Abstract

The present invention provides embryonic stem cells obtainable from an embryo of an immunodeficient mouse which is deficient in both Rag2 and Jak3 genes by culture in the presence of a GSK3 inhibitor and an MEK inhibitor, as well as a transgenic mouse, which is created with the use of these embryonic stem cells.

Claims (16)

1 . An embryonic stem cell obtainable from an embryo of an immunodeficient mouse which is deficient in both Rag2 and Jak3 genes by culture in the presence of a GSK3 inhibitor and an MEK inhibitor.

2 . The embryonic stem cell according to claim 1 , which is deposited under Accession No. NITE BP-1297.

3 . The embryonic stem cell according to claim 1 or 2 , which is engineered to have the estrogen receptor gene and the diphtheria toxin gene.

4 . The embryonic stem cell according to claim 3 , wherein the endogenous growth hormone gene in the cell is replaced with that of human origin.

5 . The embryonic stem cell according to claim 4 , wherein an endogenous drug-metabolizing enzyme gene in the cell is further replaced with that of human origin.

6 . The embryonic stem cell according to claim 5 , wherein the endogenous drug-metabolizing enzyme gene in the cell is at least one selected from the group consisting of Cyp3a11, Cyp3a13, Cyp3a25 and Cyp3a41.

7 . A mouse, which is created with the use of the embryonic stem cell according to claim 1 or 2 .

8 . A transgenic mouse, which is created with the use of the embryonic stem cell according to claim 3 .

9 . The mouse according to claim 8 , which develops liver cell injury upon administration of an antiestrogen.

10 . A mouse with a humanized liver, wherein the mouse according to claim 8 is transplanted with liver cells of human origin and also administered with an antiestrogen to eliminate liver cells originating from the mouse.

11 . The mouse according to claim 10 , wherein the liver cells of human origin are derived from a patient with a liver disease.

12 . A human liver disease model mouse, which consists of the mouse according to claim 11 .

13 . A method for preparing an immunodeficient mouse-derived embryonic stem cell, which comprises culturing an embryo of an immunodeficient mouse which is deficient in both Rag2 and Jak3 genes in the presence of a GSK3 inhibitor and an MEK inhibitor.

14 . A method for creating a liver injury model mouse, which comprises administering an antiestrogen to the mouse according to claim 8 .

15 . A method for creating a mouse with a humanized liver, which comprises transplanting liver cells of human origin into the mouse according to claim 8 and also administering an antiestrogen to eliminate liver cells originating from the mouse.

16 . The method according to claim 15 , wherein the liver cells of human origin are derived from a patient with a liver disease.

Assignments (2)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Mar 10, 2017
From: TRANS GENIC INC.
To: TRANS GENIC INC.
Reel/Frame 041962/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2014
From: YAMAMURA, KEN-ICHI; ARAKI, KIMI; OKADA, SEIJI; SHIMONO, AKIHIKO
To: TRANS GENIC INC.; NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
Reel/Frame 033821/0530 →